Biogen, on Wednesday, revealed its strategic move into the immunology space by announcing a possible acquisition of the privately held biotech company
Human Immunology Biosciences (HI-Bio) for up to $1.8 billion. According to the terms of the agreement,
Biogen will make an initial payment of $1.15 billion and could provide up to $650 million more upon achieving specific milestones. The transaction is anticipated to conclude in the third quarter of 2024, subject to antitrust approvals and other standard closing conditions.
Central to this acquisition is HI-Bio's leading candidate,
felzartamab, which is being developed to treat
IgA nephropathy (IgAN) and
primary membranous nephropathy (PMN), along with
antibody-mediated rejection (AMR) in kidney transplant patients. Felzartamab, originally intended for
multiple myeloma by
MorphoSys, is a monoclonal antibody that targets the
CD38 protein on mature plasma cells. This action helps in selectively eliminating CD38-positive cells, which are critical in diseases driven by pathological antibodies.
HI-Bio secured an exclusive license for felzartamab in November 2022, giving it rights to develop and commercialize the drug globally, except in the greater China region. Priya Singhal, who heads development at Biogen, described felzartamab as a "strategic addition" to the company's portfolio aimed at enhancing their immunology pipeline. Singhal emphasized that felzartamab had demonstrated significant effects on "key biomarkers and clinical endpoints" in three severe
renal diseases that currently lack adequate treatments.
HI-Bio has completed Phase II clinical trials for felzartamab in
AMR and PMN and is conducting a Phase II trial for IgAN. The company plans to advance all three programs to Phase III trials. Moreover, felzartamab is also being studied for
lupus nephritis in an ongoing Phase I trial.
The acquisition also grants Biogen access to HI-Bio's early-stage candidates. These include the anti-
C5aR1 antibody
izastobart, which is in Phase I trials for an undisclosed condition, and a mast cell program that is still in the discovery phase.
This acquisition follows Biogen's decision last week to terminate two neuro-programs partnered with
Ionis. The company dropped the development of
BIIB105 for
amyotrophic lateral sclerosis due to unsatisfactory Phase I/II results and chose not to pursue licensing for
BIIB121 aimed at
Angelman syndrome.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
